Results 61 to 70 of about 1,054 (155)

Situational prevention in migraine: are we doing the right thing?

The Journal of Headache and Pain
This commentary addresses the use of rimegepant for situational prevention in migraine management. While the approach of using prophylactic treatments during high-risk periods is not new, its application with rimegepant described by Lipton et al.
Lanfranco Pellesi, Paolo Martelletti
doaj   +1 more source

Effectiveness and tolerability of rimegepant in the acute treatment of migraine: a real-world, prospective, multicentric study (GAINER study)

The Journal of Headache and Pain
Background Rimegepant, a novel oral calcitonin gene-related peptide receptor antagonist, has been recently approved for the acute migraine treatment. While its efficacy was confirmed in randomized clinical trials, no data is available regarding real-life
Luigi Francesco Iannone, Gloria Vaghi, Gabriele Sebastianelli, Francesco Casillo, Antonio Russo, Marcello Silvestro, Francesca Pistoia, Giorgio Dalla Volta, Matteo Cortinovis, Alberto Chiarugi, Danilo Antonio Montisano, Maria Pia Prudenzano, Sabina Cevoli, Edoardo Mampreso, Gianluca Avino, Marina Romozzi, Mariarosaria Valente, Carla Fasano, Stefania Battistini, Antonio Granato, Elisa Maria Piella, Innocenzo Rainero, Raffaele Ornello, Roberto De Icco, On behalf of the Italian Headache Registry (RICe) Study Group   +24 more
doaj   +1 more source

Network Meta-Analysis of Calcitonin Gene-Related Peptide Receptor Antagonists for the Acute Treatment of Migraine

Frontiers in Pharmacology, 2019
Background: Research has indicated that calcitonin gene-related peptide (CGRP) receptor antagonists can be effective in the acute treatment of migraine. Six major drugs are included within this category: telcagepant, olcegepant, BI 44370, rimegepant (BMS-
Fang Xu, Wenjun Sun
doaj   +1 more source

Use of rimegepant as an alternative to triptans in migraine treatment

Quality in Sport
Introduction and aim of study: Migraine is a chronic neurological disorder that is considered one of the leading causes of disability worldwide. Increasing evidence indicates that the calcitonin gene-related peptide (CGRP), a neuropeptide released during trigeminal nerve activation, plays a major role in pathophysiology and serves as an important ...
Aleksandra Jaroń, Katarzyna Jastrzębska, Maria Witkowska, Joanna Skotnicka, Karolina Błaszczak, Monika Turek, Klara Wojciechowska, Adrian Borkowski, Mateusz Sawicki   +8 more
openaire   +2 more sources

A focus on quality of life and a swift return to normal activities for migraine sufferers

Неврология, нейропсихиатрия, психосоматика
Migraine ranks second among all conditions in terms of its impact on quality of life and work capacity, and is the leading cause of disability among people under the age of 50. Triptans, which have long been the mainstay of acute treatment, have a number
Yu. E. Azimova
doaj   +1 more source

Safety of Rimegepant in Adults with Migraine and Anxiety, Depression, or Using Antidepressants: Analysis of a Multicenter, Long-Term, Open-Label Study

Pain and Therapy
Introduction Anxiety and depression are frequently associated with migraine, and antidepressant use can complicate treatment. These analyses assessed the safety and tolerability of rimegepant in participants with migraine and anxiety and/or depression ...
David Kudrow, Susan Hutchinson, Glenn C. Pixton, Terence Fullerton   +3 more
doaj   +1 more source

Comparative effectiveness of erenumab versus rimegepant for migraine prevention using matching-adjusted indirect comparison

Journal of Comparative Effectiveness Research
Aim: To compare the efficacy of erenumab versus rimegepant as preventive treatment for patients with episodic and chronic migraine using an anchor-based matching-adjusted indirect comparison.
Ronan Mahon, Santosh Tiwari, Mirja Koch, Matias Ferraris, Keith A Betts, Yan Wang, Sophie Gao, Pascal Proot   +7 more
doaj   +1 more source

Improvements in Patient-Reported Outcome Measures Through 64 Weeks’ Rimegepant Treatment for Migraine: Analysis of a Randomized Controlled Trial with Open-Label Extension

Journal of Pain Research
Richard B Lipton,1 Dawn C Buse,1 Vincent T Martin,2 Dave Semel,3 Joseph C Cappelleri,4 Alexandra Thiry,4 Lucy Abraham,5 Terence Fullerton31Department of Neurology, Albert Einstein College of Medicine, Bronx, NY, USA; 2Headache and Facial Pain Center ...
Lipton RB, Buse DC, Martin VT, Semel D, Cappelleri JC, Thiry A, Abraham L, Fullerton T   +7 more
doaj  

Head-to-head relief: ubrogepant, rimegepant, and zavegepant in migraine treatment

Pain Management
Migraine, a significant cause of disability worldwide, heavily impacts daily functioning and quality of life. Despite various acute treatment options, including nonsteroidal anti-inflammatory drugs (NSAIDs) and triptans, patients experience limited relief or adverse effects.
Lanfranco Pellesi, Budour Jedie, Fadia Barhum, Samah Al-Abdullah, Paolo Martelletti, Zheman Xiao   +5 more
openaire   +2 more sources

Use of mediation modeling to examine the relationships among treatment with rimegepant, headache pain severity, and functional disability in patients with migraine

Cephalalgia Reports
Background Rimegepant improves both headache pain and physical function in clinical studies for the acute treatment of migraine. It is not clear whether rimegepant has direct effects on physical function or if improvements in function are an indirect ...
Lucy Abraham, Andrew G. Bushmakin, Dawn C. Buse, Joseph C. Cappelleri, David C. Semel, Elizabeth K. Seng   +5 more
doaj   +1 more source